Navigation Links
Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
Date:9/15/2009

KVISTGAARD, Denmark, September 15 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed.

This marks the first time Bavarian Nordic enters a contract with an EU country for the delivery of IMVAMUNE(R), and it demonstrates that there exists a real demand inside of EU for new and safer smallpox vaccines for preparedness stockpiles.

This contract does not affect the company's expectations for the 2009 full year results.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "Entering the first contract with an EU country on IMVAMUNE(R) demonstrates the need for new and safer smallpox vaccines. We have a continued ongoing positive dialogue with governments in and outside the EU, and we expect that this will lead to several smaller contracts. When we expectedly receive the approval from the US authorities to initiate the delivery of IMVAMUNE(R) under the RFP-3 contract for 20 million doses, this will be an important message to other governments currently considering to stockpile IMVAMUNE(R)."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE(R), a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bavarian Nordic A/S - Half Year Interim Report 2009
2. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
3. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
4. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
5. Bavarian Nordic Publishes its Annual Results 2008
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordics Case Against Oxford BioMedica
8. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
9. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
10. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
11. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 /PRNewswire/ - Last year,s petition to the White House ... efforts active to generate awareness on the importance of new organic ... the healthcare market place. ... Earlier this month Health Advance (OTC PINK: ... and nutritional products, announced its endeavors on this generally recognized ...
(Date:3/29/2017)... March 29, 2017  Applied BioMath ( ... modeling to drug research and development, today ... Zymeworks Inc. for quantitative systems pharmacology (QSP) ... for the treatment of cancer. ... for GLP toxicology studies and first-in-human dose ...
(Date:3/29/2017)... ... ... Bactana Animal Health, a company developing natural products aimed at reducing the ... gut microbiota, today announced the closing of its first round of funding. , ... Management, LLC and a number of private investors. The company will use the financing ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... and Global Markets" report to their offering. ... The study ... sequencing, biochips, RNA interference, synthetic biology tools and genome editing ... These technologies and products are analyzed to determine ...
Breaking Biology Technology:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):